Insider Trading Alert - MJN, JAZZ, FOX, IT And VR Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Friday, Nov. 15, 2013, 163 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $60.69 to $52,812,500,000.00.

Highlighted Stocks Traded by Insiders:

Mead Johnson Nutrition Company (MJN) - FREE Research Report

Golsby Stephen W who is Director at Mead Johnson Nutrition Company sold 10,000 shares at $84.08 on Nov. 15, 2013. Following this transaction, the Director owned 110,920 shares meaning that the stake was reduced by 8.27% with the 10,000 share transaction.

The shares most recently traded at $83.19, down $0.89, or 1.07% since the insider transaction. Historical insider transactions for Mead Johnson Nutrition Company go as follows:

  • 4-Week # shares bought: 500
  • 4-Week # shares sold: 10,000
  • 12-Week # shares bought: 500
  • 12-Week # shares sold: 20,525
  • 24-Week # shares bought: 10,500
  • 24-Week # shares sold: 50,525

The average volume for Mead Johnson Nutrition Company has been 1.5 million shares per day over the past 30 days. Mead Johnson Nutrition Company has a market cap of $16.3 billion and is part of the consumer goods sector and food & beverage industry. Shares are up 28.78% year to date as of the close of trading on Friday.

Mead Johnson Nutrition Company manufactures, distributes, and sells infant formulas, children's nutrition, and other nutritional products. The stock currently has a dividend yield of 1.68%. The company has a P/E ratio of 26.1. Currently there are 4 analysts that rate Mead Johnson Nutrition Company a buy, no analysts rate it a sell, and 8 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on MJN - FREE

TheStreet Quant Ratings rates Mead Johnson Nutrition Company as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, growth in earnings per share, expanding profit margins, good cash flow from operations and increase in net income. We feel these strengths outweigh the fact that the company is trading at a premium valuation based on our review of its current price compared to such things as earnings and book value. Get the full Mead Johnson Nutrition Company Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

Jazz Pharmaceuticals (JAZZ) - FREE Research Report

Falberg Kathryn E who is EVP and CFO at Jazz Pharmaceuticals sold 3,000 shares at $100.88 on Nov. 15, 2013. Following this transaction, the EVP and CFO owned 131,372 shares meaning that the stake was reduced by 2.23% with the 3,000 share transaction.

The shares most recently traded at $108.98, up $8.10, or 7.43% since the insider transaction. Historical insider transactions for Jazz Pharmaceuticals go as follows:

  • 4-Week # shares sold: 3,000
  • 12-Week # shares sold: 18,000
  • 24-Week # shares sold: 49,208

The average volume for Jazz Pharmaceuticals has been 714,300 shares per day over the past 30 days. Jazz Pharmaceuticals has a market cap of $6.3 billion and is part of the health care sector and drugs industry. Shares are up 104.11% year to date as of the close of trading on Friday.

Jazz Pharmaceuticals Public Limited Company, a specialty biopharmaceutical company, engages in the identification, development, and commercialization of pharmaceutical products for various medical needs in the United States, Europe, and other countries. The company has a P/E ratio of 20.2. Currently there are 11 analysts that rate Jazz Pharmaceuticals a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on JAZZ - FREE

TheStreet Quant Ratings rates Jazz Pharmaceuticals as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, expanding profit margins and good cash flow from operations. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full Jazz Pharmaceuticals Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

Twenty-First Century Fox (FOX) - FREE Research Report

Murdoch James R who is Dep. COO/Chair and CEO, Int'l at Twenty-First Century Fox sold 455,000 shares at $32.97 on Nov. 15, 2013. Following this transaction, the Dep. COO/Chair and CEO, Int'l owned 2.0 million shares meaning that the stake was reduced by 18.54% with the 455,000 share transaction.

The shares most recently traded at $33.52, up $0.55, or 1.64% since the insider transaction. Historical insider transactions for Twenty-First Century Fox go as follows:

  • 12-Week # shares bought: 11,000
  • 24-Week # shares bought: 11,000

The average volume for Twenty-First Century Fox has been 1.5 million shares per day over the past 30 days. Twenty-First Century Fox has a market cap of $27.0 billion and is part of the services sector and media industry.

Twenty-First Century Fox, Inc. operates as a diversified media and entertainment company worldwide. Currently there is 1 analyst that rates Twenty-First Century Fox a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on FOX - FREE

TheStreet Quant Ratings rates Twenty-First Century Fox as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance, notable return on equity, reasonable valuation levels and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Twenty-First Century Fox Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

Gartner (IT) - FREE Research Report

Dawkins Alwyn who is SVP, Events at Gartner sold 1,816 shares at $62.13 on Nov. 15, 2013. Following this transaction, the SVP, Events owned 8,556 shares meaning that the stake was reduced by 17.51% with the 1,816 share transaction.

The shares most recently traded at $64.09, up $1.96, or 3.05% since the insider transaction. Historical insider transactions for Gartner go as follows:

  • 4-Week # shares sold: 65,297
  • 12-Week # shares sold: 68,297
  • 24-Week # shares sold: 123,777

The average volume for Gartner has been 470,400 shares per day over the past 30 days. Gartner has a market cap of $5.8 billion and is part of the technology sector and computer software & services industry. Shares are up 37.96% year to date as of the close of trading on Friday.

Gartner, Inc. provides independent and objective research and analysis on information technology (IT), computer hardware, software, communications, and related technology industries. The company has a P/E ratio of 33.4. Currently there are 4 analysts that rate Gartner a buy, no analysts rate it a sell, and 4 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on IT - FREE

TheStreet Quant Ratings rates Gartner as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, impressive record of earnings per share growth, compelling growth in net income, expanding profit margins and solid stock price performance. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full Gartner Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

Validus Holdings (VR) - FREE Research Report

Greenberg Jeffrey W. who is Director at Validus Holdings sold 1.5 million shares at $39.55 on Nov. 15, 2013. Following this transaction, the Director owned 1.2 million shares meaning that the stake was reduced by 54.86% with the 1.5 million share transaction.

The shares most recently traded at $39.28, down $0.27, or 0.69% since the insider transaction. Historical insider transactions for Validus Holdings go as follows:

  • 4-Week # shares sold: 2,084
  • 12-Week # shares bought: 7,000
  • 12-Week # shares sold: 18,707
  • 24-Week # shares bought: 21,500
  • 24-Week # shares sold: 54,564

The average volume for Validus Holdings has been 657,300 shares per day over the past 30 days. Validus Holdings has a market cap of $3.9 billion and is part of the financial sector and insurance industry. Shares are up 14.2% year to date as of the close of trading on Friday.

Validus Holdings, Ltd. through its subsidiaries, provides reinsurance, insurance, and insurance linked securities fund management services in the property, marine, and specialty lines markets worldwide. The stock currently has a dividend yield of 3.05%. The company has a P/E ratio of 12.7. Currently there are 6 analysts that rate Validus Holdings a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on VR - FREE

TheStreet Quant Ratings rates Validus Holdings as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, expanding profit margins and increase in stock price during the past year. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Validus Holdings Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

Data for this article provided by Zacks Investment Research

null

More from Markets

Dow Sinks for Eighth Straight Session; Intel's CEO Departs -- ICYMI

Dow Sinks for Eighth Straight Session; Intel's CEO Departs -- ICYMI

Dow Logs Eighth Straight Drop as Stocks Slump

Dow Logs Eighth Straight Drop as Stocks Slump

This Is What's Hot Thursday - Stocks Slide, Intel's CEO Woes & Major Movers

This Is What's Hot Thursday - Stocks Slide, Intel's CEO Woes & Major Movers

U.S. Banks Pass Fed 'Stress Test' With Room for Dividends, Buybacks

U.S. Banks Pass Fed 'Stress Test' With Room for Dividends, Buybacks

U.S. Drillers at Mercy of Iran, Saudi Production Spat as OPEC Meeting Begins

U.S. Drillers at Mercy of Iran, Saudi Production Spat as OPEC Meeting Begins